| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Mixed Poisson Regression Model for Analysis of Patent Data |
0 |
0 |
0 |
290 |
1 |
4 |
9 |
1,722 |
| Are All Patent Examiners Equal? The Impact of Examiner Characteristics |
0 |
0 |
0 |
364 |
0 |
0 |
13 |
1,947 |
| Balancing Incentives: The Tension Between Basic and Applied Research |
0 |
0 |
0 |
416 |
1 |
3 |
19 |
1,843 |
| Characteristics of Demand for Pharmaceutical Products: an Examination of four Cephalosporins |
0 |
0 |
0 |
0 |
0 |
2 |
10 |
2,341 |
| Deals Not Done: Sources of Failure in the Market for Ideas |
0 |
1 |
2 |
29 |
0 |
1 |
11 |
77 |
| Do Patents Matter?: Empirical Evidence after GATT |
0 |
0 |
2 |
290 |
1 |
1 |
12 |
798 |
| Entry and Patenting in the Software Industry |
0 |
1 |
2 |
188 |
1 |
2 |
11 |
613 |
| Faster, Smaller, Cheaper: An Hedonic Price Analysis of PDAs |
0 |
0 |
0 |
100 |
0 |
0 |
3 |
386 |
| Generics and New Goods in Pharmaceutical Price Indexes |
0 |
0 |
0 |
265 |
1 |
3 |
15 |
1,201 |
| Gone But Not Forgotten: Labor Flows, Knowledge Spillovers, and Enduring Social Capital |
0 |
0 |
0 |
259 |
0 |
0 |
6 |
800 |
| Hedonic Analysis of Arthritis Drugs |
0 |
0 |
0 |
162 |
0 |
0 |
8 |
1,007 |
| Industry Effects and Appropriability Measures in the Stock Markets Valuation of R&D and Patents |
0 |
2 |
6 |
374 |
2 |
4 |
18 |
1,113 |
| Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs |
0 |
0 |
0 |
154 |
0 |
0 |
6 |
1,619 |
| Market Conditions and Retirement of Physical Capital: Evidence fron Oil Tankers |
0 |
0 |
0 |
44 |
0 |
0 |
2 |
461 |
| Measuring competence?: exploring firm effects in pharmaceutical research |
1 |
2 |
5 |
505 |
2 |
8 |
42 |
1,293 |
| Not Invented Here? Innovation in Company Towns |
0 |
0 |
2 |
83 |
0 |
0 |
9 |
307 |
| Patent Thickets, Licensing and Innovative Performance |
0 |
1 |
1 |
128 |
0 |
1 |
8 |
386 |
| Patent thickets, licensing and innovative performance |
0 |
1 |
1 |
56 |
0 |
2 |
8 |
137 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
2 |
71 |
1 |
4 |
27 |
125 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
1 |
50 |
1 |
2 |
16 |
93 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
1 |
29 |
1 |
4 |
21 |
79 |
| Patents and the Survival of Internet-related IPOs |
0 |
1 |
1 |
82 |
1 |
4 |
13 |
268 |
| Patents and the global diffusion of new drugs |
0 |
0 |
0 |
18 |
1 |
3 |
17 |
62 |
| Patents and the global diffusion of new drugs |
0 |
1 |
2 |
53 |
1 |
3 |
21 |
75 |
| Patents, Thickets, and the Financing of Early-Stage Firms: Evidence from the Software Industry |
0 |
0 |
0 |
98 |
1 |
1 |
8 |
319 |
| Price Indexes for Clinical Trial Research: A Feasibility Study |
1 |
1 |
1 |
21 |
2 |
4 |
10 |
49 |
| Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research |
0 |
0 |
0 |
123 |
0 |
0 |
12 |
351 |
| Public-Private Interaction and the Productivity of Pharmaceutical Research |
0 |
0 |
0 |
185 |
0 |
1 |
18 |
739 |
| Racing or spilling?: the determinants of research productivity in ethical drug discovery |
0 |
1 |
1 |
52 |
0 |
2 |
16 |
184 |
| Racing to invest?: the dynamics of competition in ethical drug discovery |
1 |
3 |
6 |
288 |
2 |
6 |
22 |
570 |
| Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery |
0 |
0 |
0 |
1 |
1 |
5 |
18 |
456 |
| Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry |
0 |
0 |
1 |
346 |
2 |
4 |
27 |
998 |
| Scale, scope and spillovers: the determinants of research productivity in ethical drug discovery |
0 |
0 |
0 |
144 |
2 |
3 |
18 |
308 |
| The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research |
0 |
0 |
0 |
308 |
0 |
2 |
27 |
1,910 |
| The Impact of Artificial Intelligence on Innovation |
4 |
16 |
78 |
238 |
18 |
87 |
1,728 |
2,350 |
| The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity |
0 |
0 |
0 |
53 |
0 |
0 |
5 |
83 |
| University Research, Industrial R&D, and the Anchor Tenant Hypothesis |
0 |
0 |
0 |
223 |
1 |
4 |
23 |
906 |
| Why are Some Regions More Innovative than Others? The Role of Firm Size Diversity |
0 |
0 |
2 |
95 |
1 |
3 |
11 |
253 |
| Why are some regions more innovative than others? The role of firm size diversity |
0 |
0 |
0 |
83 |
1 |
2 |
9 |
69 |
| Total Working Papers |
7 |
31 |
117 |
6,268 |
46 |
175 |
2,277 |
28,298 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery |
0 |
1 |
11 |
310 |
3 |
9 |
47 |
1,205 |
| Access to intellectual property for innovation: Evidence on problems and coping strategies from German firms |
0 |
1 |
4 |
20 |
0 |
1 |
12 |
104 |
| Analysis of Patent Data--A Mixed-Poisson-Regression-Model Approach |
0 |
0 |
0 |
0 |
0 |
1 |
11 |
902 |
| Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins |
0 |
0 |
0 |
404 |
0 |
1 |
3 |
1,135 |
| Deals not done: Sources of failure in the market for ideas |
0 |
0 |
2 |
4 |
0 |
0 |
17 |
50 |
| Diffusion of New Drugs in the Post-TRIPS Era |
0 |
0 |
1 |
50 |
0 |
0 |
4 |
157 |
| Entry and Patenting in the Software Industry |
0 |
2 |
5 |
40 |
1 |
5 |
18 |
208 |
| Faster, smaller, cheaper: an hedonic price analysis of PDAs |
1 |
2 |
3 |
39 |
3 |
7 |
26 |
229 |
| Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy |
0 |
1 |
2 |
22 |
0 |
1 |
6 |
88 |
| Generics and New Goods in Pharmaceutical Price Indexes |
0 |
0 |
5 |
219 |
0 |
3 |
22 |
882 |
| Generics and New Goods in Pharmaceutical Price Indexes: Reply |
0 |
0 |
0 |
33 |
0 |
0 |
3 |
166 |
| Industry Effects and Appropriability Measures in the Stock Market's Valuation of R&D and Patents |
3 |
7 |
23 |
305 |
5 |
12 |
66 |
1,030 |
| Information Technology and Intangible Output: The Impact of IT Investment on Innovation Productivity |
1 |
3 |
5 |
7 |
3 |
7 |
18 |
32 |
| Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs |
0 |
0 |
0 |
28 |
0 |
3 |
11 |
368 |
| Measuring Competence? Exploring Firm Effects in Pharmaceutical Research |
0 |
0 |
4 |
5 |
1 |
3 |
27 |
39 |
| New Pills for Poor People? Empirical Evidence after GATT |
0 |
1 |
1 |
230 |
0 |
2 |
10 |
502 |
| Not Invented Here? Innovation in company towns |
1 |
3 |
4 |
31 |
1 |
6 |
22 |
277 |
| Opportunity costs and entrepreneurial activity |
1 |
5 |
9 |
127 |
4 |
12 |
53 |
372 |
| Patent thickets, licensing and innovative performance |
0 |
1 |
5 |
34 |
1 |
2 |
18 |
123 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
5 |
68 |
3 |
10 |
49 |
302 |
| Patents and the survival of Internet-related IPOs |
1 |
1 |
6 |
72 |
3 |
11 |
35 |
326 |
| Patents, Thickets and the Financing of Early-Stage Firms: Evidence from the Software Industry |
0 |
1 |
1 |
70 |
0 |
2 |
15 |
309 |
| Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs |
0 |
0 |
0 |
0 |
0 |
1 |
7 |
12 |
| Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs |
0 |
0 |
0 |
2 |
0 |
1 |
9 |
14 |
| Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research |
1 |
2 |
5 |
13 |
2 |
8 |
32 |
70 |
| Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery |
0 |
0 |
0 |
0 |
1 |
7 |
26 |
600 |
| Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research |
1 |
6 |
10 |
219 |
1 |
11 |
32 |
547 |
| Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery |
1 |
6 |
34 |
531 |
8 |
30 |
115 |
1,593 |
| The Economics of Reproducibility in Preclinical Research |
1 |
2 |
2 |
2 |
1 |
2 |
4 |
4 |
| The Global Location of Biopharmaceutical Knowledge Activity: New Findings, New Questions |
0 |
0 |
0 |
5 |
0 |
2 |
4 |
44 |
| The Impact of Incremental Innovation in Biopharmaceuticals |
0 |
0 |
0 |
11 |
0 |
0 |
3 |
44 |
| The anchor tenant hypothesis: exploring the role of large, local, R&D-intensive firms in regional innovation systems |
0 |
2 |
13 |
156 |
3 |
9 |
36 |
551 |
| Untangling the origins of competitive advantage |
0 |
0 |
0 |
0 |
0 |
1 |
7 |
10 |
| Why are some regions more innovative than others? The role of small firms in the presence of large labs |
1 |
2 |
8 |
62 |
5 |
10 |
41 |
240 |
| Total Journal Articles |
13 |
49 |
168 |
3,119 |
49 |
180 |
809 |
12,535 |
LogEc is hosted by the
Örebro University School of Business.